Evaluation of Diphenhydramine As a Sedative for Dogs EXOTIC Erik H

Total Page:16

File Type:pdf, Size:1020Kb

Evaluation of Diphenhydramine As a Sedative for Dogs EXOTIC Erik H 04-03-0142.qxp 3/11/2005 11:40 AM Page 1092 Evaluation of diphenhydramine as a sedative for dogs EXOTIC Erik H. Hofmeister, DVM, and Christine M. Egger, DVM, MVSc, DACVA SMALL ANIMALS/ slows physical reaction time.3,4 It is indicated for use in allergic conditions, motion sickness, and Parkinson’s Objective—To determine and compare levels of disease.5 In a survey6 of 19,108 patients after conscious sedation achieved by IM administration of diphenhy- surgery for cataract removal, inclusion of diphenhy- dramine, saline (0.9% NaCl) solution, and acepro- dramine in the preanesthetic protocol resulted in sub- mazine in dogs. stantial reduction in incidence of pain during surgery; Design—Prospective randomized study. reduction in dissatisfaction with pain management; Animals—56 dogs. and reduction in incidence of postoperative drowsi- Procedure—Dogs were randomly assigned to ness, nausea, and vomiting. If diphenhydramine had receive diphenhydramine at 2, 4, or 8 mg/kg (0.9, 1.8, similar effects in dogs, its routine inclusion as part of a or 3.6 mg/lb, respectively) IM; acepromazine at 0.1 preanesthetic medication would be warranted. mg/kg (0.05 mg/lb) IM; or saline solution at 0.05 The sedative effects of diphenhydramine in dogs mL/kg (0.02 mL/lb) IM. Sedation was assessed by have been reported only in a secondary reference7 and use of a 6-category descriptive system based on have not been specifically studied in a prospective, ran- observation and interaction. domized, controlled research trial. The purpose of the Results—Dogs in the acepromazine group had signif- study reported here was to determine the sedative icantly higher sedation scores than did dogs in the effects of administration of diphenhydramine in dogs. saline solution or diphenhydramine groups at 30 min- utes. Dogs in the diphenhydramine groups did not have significantly different sedation scores from dogs Materials and Methods in the saline solution group at any time point. Fifty-six random-source (obtained from municipal shel- Conclusions and Clinical Relevance—Diphenhydra- ters), mixed-breed dogs that were anesthetized for a surgical mine did not cause clinically appreciable sedation in exercises laboratory were used in the study. There were 8 healthy dogs. Diphenhydramine is not suitable as a sole dogs in a negative control group that received only saline sedative prior to general anesthesia in dogs. (J Am Vet (0.9% NaCl) solution and 12 dogs in each of 4 other groups. Med Assoc 2005;226:1092–1094) The protocol was approved by the University of Georgia Animal Care and Use Committee, and husbandry was pro- vided according to established institutional guidelines. Any dog deemed unhealthy because of results of physical exami- iphenhydramine is an H1 receptor antagonist used in 1 nation or with an abnormal PCV or total protein concentra- Da variety of allergic conditions. Because of its antihis- tion was excluded. Body condition score (BCS) was assessed taminic and anticholinergic properties, it may cause seda- by use of a previously published system.8 Dogs were ran- tion as an adverse effect in humans.2 Because of this effect, domly assigned to groups that received saline solution (0.05 many practitioners use diphenhydramine for mild seda- mL/kg [0.02 mL/lb], IM), diphenhydraminea (2, 4, or 8 tion in dogs, including sedation for travel, during stress- mg/kg [0.9, 1.8, or 3.6 mg/lb, respectively] IM), or acepro- ful experiences, or before anesthetic induction. Diphen- mazineb (0.1 mg/kg [0.05 mg/lb], IM [positive control hydramine is frequently used in our hospital as a pre- group]). All IM injections were made in the caudal epaxial medication agent before anesthesia in patients with mast musculature by an experienced individual. A single individual (EHH), blinded to treatment group, cell tumors in an attempt to decrease histamine effects performed all sedation scoring. Dogs were housed individual- that result from degranulation of mast cells associated ly during sedation scoring and for at least 12 hours before ini- with tumor manipulation. Diphenhydramine is inexpen- tiation of the study. Dogs were acclimated to the presence of sive, is not a controlled substance, causes minimal cardio- the observer for approximately 10 minutes before administra- vascular suppression, and is readily accessible to general tion of a test substance. During data collection, the dogs were practitioners. All these qualities make it a potentially valu- allowed to move freely in their cages. Sedation scores were able drug for use as a sedative before anesthesia. obtained before administration and at 10, 20, and 30 minutes after administration by use of a modification of a previously In humans, diphenhydramine causes drowsiness, 9 impedes performance on mental cognition tests, and published objective scoring system. A score for analgesia was removed from the original system because none of the drugs administered in this study would be expected to provide anal- From the Departments of Large Animal Medicine (Hofmeister) and Small Animal Medicine and Surgery (Egger), College of Veterinary gesia. The total sedation score for each dog at each time point Medicine, University of Georgia, Athens, GA 30602. Dr. Hofmeister’s was calculated by adding all values for all 6 categories togeth- present address is Department of Small Animal Medicine and er. Any adverse effects were recorded. Between recordings, the Surgery, College of Veterinary Medicine, University of Georgia, observer walked between dog cages, further acclimating the Athens, GA 30602. Dr. Egger’s present address is Department of dogs to the observer’s presence. Small Animal Clinical Sciences, College of Veterinary Medicine, The sedation data were analyzed for normality, and para- University of Tennessee, Knoxville, TN 37996. metric statistics were used for data analysis. For sedation scores, The authors thank Dr. C. Rawlings for technical assistance. weight in kilograms, and BCS, a 1-way ANOVA was used for Address correspondence to Dr. Hofmeister. comparisons among groups. Post hoc analysis was performed by 1092 Scientific Reports: Original Study JAVMA, Vol 226, No. 7, April 1, 2005 04-03-0142.qxp 3/11/2005 11:40 AM Page 1093 Table 1—Mean ± SD sedation scores in dogs given diphenhy- to-5 scoring systems to systems as detailed as the one SMALL ANIMALS/ dramine (2, 4, or 8 mg/kg [0.9, 1.8, or 3.6 mg/lb, respectively], 10-12 IM, [D2, D4, and D8, respectively]), acepromazine (0.1 mg/kg used in the study reported here. None of the seda- [0.05 mg/lb], IM [ACE]), or saline (0.9% NaCl) solution (0.05 tion scoring systems reviewed in the veterinary litera- EXOTIC mL/kg [0.02 mL/lb], IM [SAL]) before (time 0) and 10, 20, and 30 ture has been fully validated. A more detailed scoring minutes after administration. system could not be located in the literature or inde- Time (min) pendently derived, so we believe that the system we used was as sensitive as possible in a clinical setting. Group 0 10 20 30 It is possible that diphenhydramine causes seda- D2 –3.25 Ϯ 3.33 –0.67 Ϯ 2.77a 0.0 Ϯ 2.89a 1.0 Ϯ 2.89a tion only after oral administration. The pharmacoki- D4 –0.58 Ϯ 3.37 0.25 Ϯ 2.8 1.0 Ϯ 2.95 1.75 Ϯ 3.86a D8 –1.08 Ϯ 2.54 1.83 Ϯ 2.25a 2.0 Ϯ 2.80a 3.08 Ϯ 2.15a netics of diphenhydramine in dogs have been evaluat- ACE –2.33 Ϯ 4.14 1.17 Ϯ 2.95a 3.17 Ϯ 3.16a 6.08 Ϯ 2.97a,b ed only in 1 publication, which reported data from SAL –2.13 Ϯ 4.91 –0.63 Ϯ 3.58 1.13 Ϯ 4.32a 1.5 Ϯ 3.89a only 2 dogs.13 Thus, we cannot comment on the Maximum possible sedation score is 14. bioavailability or plasma concentrations of diphenhy- aSignificantly (P Ͻ 0.05) different from value at time 0. dramine after administration PO or IM, and we cannot bSignificantly (P Ͻ 0.05) different from SAL, D2, D4, and D8 at this correlate sedation levels with plasma concentrations of time point. the drug because this was not investigated. We recorded sedation scores for 30 minutes after use of the Tukey multiple-comparison test. A 1-way ANOVA for administration, which may have been inadequate for repeated measures was used to test for changes within a treat- ment group over time. When significance was found, post hoc efficacious plasma concentrations to be reached. analysis was performed by use of the Tukey multiple-compari- However, in cats, behavior changes were observed as son test. A commercial statistical software package was used for early as 30 minutes after oral administration of diphen- all analyses.c Statistical significance was set at P < 0.05. hydramine at 3 mg/kg (1.4 mg/lb).14 We chose to stop recording sedation at 30 minutes because, when evalu- Results ated for use as a sedative before anesthesia, an onset There were no significant differences among time > 30 minutes is not likely to be clinically useful. groups for weight or BCS. There were no significant However, if sedation occurs at a later time point, the differences among groups for sedation scores at 0, 10, drug may contribute to increased anesthetic depth or and 20 minutes. At 30 minutes, mean sedation score in prolonged recovery time after general anesthesia. the acepromazine group was significantly higher than The dogs in the present study were all random- that in the saline solution or diphenhydramine groups. source, healthy young dogs. Many were either quite agi- Sedation scores increased over time for all groups tated and energetic or somewhat frightened and timid.
Recommended publications
  • Anesthesia and Analgesia in Laboratory Animals
    GUIDELINES ON ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS University of South Florida provides the following guidelines for use by IACUC-certified faculty and staff. CONTENTS PAGE A. Background……………………………………………………….…………………………… 1 B. Definitions....……………………………………………………..…………………………….. 2 C. General Considerations……………………………………….,…………………………….. 3 D. Controlled Substances……………………………………….……………………………… 3 E. Pre-Anesthetic Treatments………………………………….………………………………. 4 F. General Anesthetics………………………………………….………………………………. 4 G. Neuromuscular Blocking Agents………………………….……………………………….. 5 H. Monitoring Anesthesia…………………………………….…………………………………. 6 I. Analgesics……………………………………………………………………………………… 7 J. Comments regarding Anesthetics and Analgesics……………………………………... 7 REFERENCE TABLES PAGE I. Signs of Pain and Distress in Laboratory Animals………………………………………… 10 II. Commonly Used Anesthetics and Analgesics for Mice….………..…...….………...…… 11 III. Commonly Used Anesthetics and Analgesics for Rats……………………………...…… 12 IV. Commonly Used Anesthetics and Analgesics for Gerbils……….……………..…….. 13 V. Commonly Used Anesthetics and Analgesics for Hamsters…….……………..……. 14 VI. Commonly Used Anesthetics and Analgesics for Guinea Pigs….…………….….……. 15 VII. Commonly Used Anesthetics and Analgesics for Rabbits.……...…………….………… 16 VIII. Commonly Used Anesthetics and Analgesics for Dogs.…………………….…………… 17 IX. Commonly Used Anesthetics and Analgesics for Cats.……………………..…………… 18 X. Commonly Used Anesthetics and Analgesics for Pigs ..……………..….………………..19 XI. Commonly Used Anesthetics and Analgesics
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Dr Michael Crowley Professor Malcolm Dando
    DOWN THE SLIPPERY SLOPE? A STUDY OF CONTEMPORARY DUAL-USE CHEMICAL AND LIFE SCIENCE RESEARCH POTENTIALLY APPLICABLE TO INCAPACITATING CHEMICAL AGENT WEAPONS BIOCHEMICAL SECURITY 2030 POLICY PAPER SERIES NUMBER 8 BIOCHEMICAL SECURITY 2030 PROJECT BRADFORD NON-LETHAL WEAPONS RESEARCH PROJECT OCTOBER 2014 Dr Michael Crowley Project Coordinator of the Bradford Non-Lethal Weapons Research Project based at the Peace Studies Department, School of Social and International Studies, University of Bradford, United Kingdom. Email: [email protected] Professor Malcolm Dando School of Social and International Studies University of Bradford, Bradford Email: [email protected] ACKNOWLEDGEMENTS The authors, as well as the Biochemical Security 2030 Project organisers, would like to thank those who have reviewed or commented upon drafts of this report. In particular this includes Professor Julian Perry Robinson and Dr Ralf Trapp as well as others, including those members of the Biochemical Security 2030 expert panel, who commented on this document. We are also grateful to those Government officials, named and unnamed, who have replied to our information requests and/or commented upon specific sections of this report. We are grateful to the Economic and Social Research Council as well as the Defence Science and Technology Laboratory Futures and Innovation Domain for funding the Biochemical Security 2030 Project. The authors would also like to express their gratitude to the Joseph Rowntree Charitable Trust for their financial support for aspects of this research. The research findings and policy recommendations detailed in this publication have been developed under the auspices of the Bradford Non-Lethal Weapons Research Project (BNLWRP) and reflect the organisation's position on these issues.
    [Show full text]
  • Pain Management in Patients with Substance-Use Disorders
    Pain Management in Patients with Substance-Use Disorders By Valerie Prince, Pharm.D., FAPhA, BCPS Reviewed by Beth A. Sproule, Pharm.D.; Jeffrey T. Sherer, Pharm.D., MPH, BCPS; and Patricia H. Powell, Pharm.D., BCPS Learning Objectives regarding drug interactions with illicit substances or prescribed pain medications. Finally, there are issues 1. Construct a therapeutic plan to overcome barri- ers to effective pain management in a patient with related to the comorbidities of the patient with addic- addiction. tion (e.g., psychiatric disorders or physical concerns 2. Distinguish high-risk patients from low-risk patients related to the addiction) that should influence product regarding use of opioids to manage pain. selection. 3. Design a treatment plan for the management of acute pain in a patient with addiction. Epidemiology 4. Design a pharmacotherapy plan for a patient with Pain is the second most common cause of work- coexisting addiction and chronic noncancer pain. place absenteeism. The prevalence of chronic pain may 5. Design a pain management plan that encompasses be much higher among patients with substance use dis- recommended nonpharmacologic components for orders than among the general population. In the 2006 a patient with a history of substance abuse. National Survey on Drug Use and Health, past-year alco- hol addiction or abuse occurred in 10.3% of men and 5.1% of women. In the same survey, 12.3% of men and Introduction 6.3% of women were reported as having a substance-use Pain, which is one of the most common reasons disorder (abuse or addiction) during the past year.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]
  • The Pharmacokinetics of Medetomidine Administered Subcutaneously During Isoflurane Anaesthesia in Sprague-Dawley Rats
    animals Article The Pharmacokinetics of Medetomidine Administered Subcutaneously during Isoflurane Anaesthesia in Sprague-Dawley Rats Leila T. Kint 1, Bhedita J. Seewoo 2,3,4 , Timothy H. Hyndman 5 , Michael W. Clarke 6, Scott H. Edwards 7, Jennifer Rodger 3,4, Kirk W. Feindel 2,8 and Gabrielle C. Musk 1,9,* 1 Faculty of Health and Medical Sciences, The University of Western Australia, Perth 6009, Australia; [email protected] 2 Centre for Microscopy, Characterisation and Analysis, Research Infrastructure Centres, The University of Western Australia, Perth 6009, Australia; [email protected] (B.J.S.); [email protected] (K.W.F.) 3 Experimental and Regenerative Neurosciences, School of Biological Sciences, The University of Western Australia, Perth 6009, Australia; [email protected] 4 Brain Plasticity Group, Perron Institute for Neurological and Translational Science, Perth 6009, Australia 5 School of Veterinary Medicine, Murdoch University, Perth 6150, Australia; [email protected] 6 Metabolomics Australia, Centre for Microscopy, Characterisation and Analysis, The University of Western Australia, Perth 6009, Australia; [email protected] 7 School of Animal Veterinary Sciences, Charles Sturt University, Wagga Wagga 2650, Australia; [email protected] 8 School of Biomedical Sciences, the University of Western Australia, Perth 6009, Australia 9 Animal Care Services, the University of Western Australia, Perth 6009, Australia * Correspondence: [email protected] Received: 28 May 2020; Accepted: 17 June 2020; Published: 18 June 2020 Simple Summary: Rodents, including rats, are used as animal models for research investigating neurological diseases in humans. To enable this research the animals are anaesthetized to facilitate imaging of the brain, but the anaesthetic drugs impact the results of the research.
    [Show full text]
  • Gamma Hydroxybutyrate (GHB)
    If you have issues viewing or accessing this file, please contact us at NCJRS.gov. PROPERTY OF Executive Office of the President National CriminalJustice Reference Service (NOJRS) ~.~1~<~ ~ )~ Office of National Drug Control Policy Box 6000 \~~/ Rockvilte, MD 20849-6000 L lohn P. Waiters, Director www.whitchousedrugpolicy.gov 1-800-666-333~ Gamma Hydroxybutyrate (GHB) / Backgrou nd liquid packaged in vials or sma.ll bottles. In liquid form, Gamma hydroxybutyrate (GHB) is a powerful, rapidly it is clear, odorless, tasteless, and almost undetectable acting central nervous system depressant. It was first when mixed in a drink. GHB is typically consumed by synthesized in the 1920s and was under development as the capful or teaspoonful at a cost of $5 to $10 per dose. an anesthetic agent in the 1960s. GHB is produced nat- The average dose is I to 5 grams and takes effect in 15 urally by the body in small amounts but its physiologi- to 30 minutes, depending on the dosage and purity of cal function is unclear. the drug. Its effects last from 3 to 6 hours. GHB was sold in health food stores as a performance- Consumption of less than l gram of GHB acts as a enhancing additive in bodybuilding formulas until the relaxant, causing a loss of muscle tone and reduced Food and Drug Administration (FDA) banned it in inhibitions. Consumption of I to 2 grams causes a 1990. It is currently marketed in some European coun- strong feeling of relaxation and slows the heart rate tries as an adjunct to anesthesia. GHB is abused for its and respiration.
    [Show full text]
  • Sedative / Hypnotics
    Sedative / Hypnotics Robert Althoff, MD, PhD www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose: ▪ I receive or have received research support from NIMH, NIDA, and the Klingenstein Third Generation Foundation ▪I have ownership equity in WISER Systems, LLC as a partner. www.mghcme.org www.mghcme.org • Sedative / Hypnotics are a general class of agents • Frequently refer to benzodiazepines (and like compounds) and barbiturates • Many similarities in mechanisms of action, medical indications, behavioral effects, withdrawal considerations, and treatment www.mghcme.org Benzodiazepine Mechanism of Action Benzodiazepines are a class of agents that work on the central nervous system, acting selectively on gamma-aminobutyric acid-A (GABA-A) receptors in the brain. It enhances response to the inhibitory neurotransmitter GABA, by opening GABA-activated chloride channels and allowing chloride ions to enter the neuron, making the neuron negatively charged and resistant to excitation www.mghcme.org • Traditional benzodiazepines – Diazepam (Valium) – Clonazepam (Klonopin) – Others • “Z” Drugs – Zaleplon (trade: Sonata) – Zolpidem (trade: Ambien, Edluar, Intermezzo) – Zopiclone (trade: Zimovane) www.mghcme.org Benzodiazepine: General Info • C IV DEA classification • Although more than 2,000 different benzodiazepines have been produced worldwide, only about 15 are currently FDA-approved in the United States. • Types of benzodiazepines therefore include those the following – Ultra-short acting: midazolam (Versed), triazolam (Halcion) – Short-acting: alprazolam (Xanax), lorazepam (Ativan) – Long-acting: chlordiazepoxide (Librium), diazepam (Valium) • The use of benzodiazepines during pregnancy is a risk factor for cleft lip or palate, lower muscle tone, and withdrawal symptoms in the developing fetus Bachhuber, et al.
    [Show full text]
  • Doxepin (Silenor) for Insomnia DHIREN PATEL, Pharmd, and JENNIFER D
    STEPS New Drug Reviews Doxepin (Silenor) for Insomnia DHIREN PATEL, PharmD, and JENNIFER D. GOLDMAN-LEVINE, PharmD Massachusetts College of Pharmacy and Health Sciences, Boston, Massachusetts STEPS new drug reviews Silenor is a new low-dose formulation of the tricyclic antidepressant doxepin (which is typi- cover Safety, Tolerability, cally taken as a 25- to 150-mg dose at bedtime). Low-dose doxepin is labeled for the treatment Effectiveness, Price, and Simplicity. Each indepen- of insomnia characterized by difficulty maintaining sleep. The exact mechanism by which the dent review is provided medication exerts its sleep maintenance effect is unknown, but is thought to be antagonism 1 by authors who have no of histamine H1 receptors. financial association with the drug manufacturer. The series coordinator for Drug Dosage Dose form Monthly cost* AFP is Allen F. Shaugh- nessy, PharmD, Tufts Doxepin (Silenor) 3 to 6 mg daily 3-mg and 6-mg tablets $208 University Family Medicine Residency Program at *—Price for 30 3-mg or 6-mg tablets at CVS Pharmacy on May 18, 2011. Cambridge Health Alli- ance, Malden, Mass. A collection of STEPS pub- lished in AFP is available SAFETY of 1,017 patients, approximately 1 percent at http://www.aafp.org/ 1 afp/steps. Doxepin is safe when used at low dosages. withdrew because of adverse effects. Rebound Antidepressants are required to have label- insomnia and withdrawal symptoms have not ing that warns of an increased risk of sui- been reported. Next-day sedation, anticholin- cide; however, there have been no reports ergic effects, and memory impairment do not of suicide among patients taking low-dose occur at low dosages.2,3 The use of central ner- doxepin.
    [Show full text]
  • Effect of Intramuscular Medetomidine Administration on Tear Flow in Rats
    veterinary sciences Communication Effect of Intramuscular Medetomidine Administration on Tear Flow in Rats Teppei Kanda 1,2,* , Yuka Mizoguchi 2, Kayo Furumoto 1,2, Yuki Shimizu 1,2, Noritaka Maeta 1,2 and Toshinori Furukawa 3 1 Faculty of Veterinary Medicine, Okayama University of Science, 1-3 Ikoino-oka, Imabari, Ehime 794-8555, Japan 2 Department of Comparative Animal Science, College of Life Science, Kurashiki University of Science and the Arts, 2640 Nishinoura, Tsurajima-cho, Kurashiki, Okayama 712-8505, Japan 3 Department of Animal Pharmaceutical Science, School of Pharmaceutical Science, Kyushu University of Health and Welfare, 1714-1 Yoshino-cho, Nobeoka, Miyazaki 882-8508, Japan * Correspondence: [email protected] Received: 19 March 2020; Accepted: 10 April 2020; Published: 13 April 2020 Abstract: Medetomidine has been reported to decrease tear flow significantly in dogs, cats, and pigs when used as a sedative or analgesic; however, there are no such reports when it comes to rats. The present study aimed to investigate the effect of medetomidine on tear flow in rats. Medetomidine in doses of 50, 100, or 200 µg/kg or a physiological saline solution as the control, were administered intramuscularly to male Slc:Wistar/ST rats. After the administration of medetomidine, tear flow in both eyes was measured using a phenol red thread tear test. The area under the curve (AUC) of phenol red thread test values from baseline to 8 h was calculated. Data were plotted against the dose of medetomidine and simple linear regression analysis was performed. The effect of the drug on phenol red thread test values was considered dose-related when linear analysis yielded a significant relationship.
    [Show full text]
  • Phenibut and EMS Earlier This Week, the Michigan Poison Center
    Phenibut and EMS Earlier this week, the Michigan Poison Center (MPP) received an inquiry from a UP emergency physician who had cared for two patients in two days who had been abusing a substance called Phenibut, a synthetically produced central nervous system depressant with similarities to the neurotransmitter known as GABA. Phenibut is not an FDA approved or regulated drug. It typically is marketed as a dietary substitute and is readily available in stores (especially “headshops”) and online. While officially considered a supplement, it is felt to have properties more similar to a prescription sedative. It is marketed outside of the US for depression, anxiety, and posttraumatic stress disorder. Recently Phenibut has been recognized as having the potential for physical dependence, withdrawal, and addiction.1,2 In response to the UP physician’s concern that these two cases might be part of an increase in Phenibut use, the MPC initiated a review, identifying 12 cases this year.3 They also notified MDHHS of the concern. The Division of EMS and Trauma, using Michigan EMS Information System data identified 8 cases in the first 11 months of 2019 compared to 5 cases in the last 6 months of 2018. One EMS case was also identified by MPC. Of the combined 19 cases from 2019, one third occurred in the Upper Peninsula, with 5 of the 8 cases (62.5%) in the last 6 months coming from the UP. Cases were reported in 10 Michigan counties. Documented coingestants were noted in 36.8% of the cases and included cannabinoids (2), kratom (3), ETOH, Flakka (bath salts), and other medications.
    [Show full text]